Netarsudil
- TRADE NAME: Rhopressa (Aerie)
- INDICATIONS: Reduction of elevated intraocular pressure in open angle glaucoma or ocular hypertension
- CLASS: Rho kinase inhibitor
- HALF-LIFE: N/A
FDA APPROVAL DATE: 12/18/2017
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
No available data to inform drug-associated risk
Please login to see the rest of this drug profile
LOCAL.
OCULAR.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric